Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention


  Free Subscription


1 Am J Med
15 Ann Intern Med
1 Antiviral Res
1 Cell
1 Drug Saf
2 Eur J Epidemiol
3 J Clin Microbiol
6 J Epidemiol Community Health
2 J Immunol
1 J Infect
7 J Infect Dis
3 J Virol
2 Lancet
1 MMWR Morb Mortal Wkly Rep
9 N Engl J Med
2 PLoS Comput Biol
1 PLoS Genet
2 PLoS Med
42 PLoS One
6 Proc Natl Acad Sci U S A
23 Vaccine
1 Virology
7 Virus Res

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    Am J Med

  1. CREES ZD, Stockerl-Goldstein K
    COVID-19 and Light Chain Amyloidosis, Adding Insult to Injury.
    Am J Med. 2022;135 Suppl 1:S49-S52.
    PubMed         Abstract available

    Ann Intern Med

  2. CENTOR RM, Kertesz SG
    Web Exclusive. Annals On Call - Evidence-Based Care of Substance Use Disorders.
    Ann Intern Med. 2022;175:OC1.

  3. BURDEN M, Chopra V
    Web Exclusive. Annals for Hospitalists Inpatient Notes - COVID-19, Hospital Medicine, and a Way Forward.
    Ann Intern Med. 2022;175:HO2-HO3.

    Moderna COVID-19 vaccine was linked to myocarditis or myopericarditis at 28 d (4.2 events/100 000 persons).
    Ann Intern Med. 2022 May 3. doi: 10.7326/J22-0021.
    PubMed         Abstract available

  5. MOURAD O, Chagla Z
    In high-risk outpatients with COVID-19, remdesivir reduced COVID-19-related hospitalization or all-cause death at 28 d.
    Ann Intern Med. 2022 May 3. doi: 10.7326/J22-0026.
    PubMed         Abstract available

  6. SINGH KP, Tong SYC
    In adults hospitalized with COVID-19, adding remdesivir to standard care did not reduce in-hospital mortality.
    Ann Intern Med. 2022 May 3. doi: 10.7326/J22-0025.
    PubMed         Abstract available

    In adults who had not had COVID-19, Novavax vaccine had 90% efficacy at >/=7 d after the second dose.
    Ann Intern Med. 2022 May 3. doi: 10.7326/J22-0028.
    PubMed         Abstract available

  8. CENTOR RM, Syed FZ
    Annals On Call - Type 1 Diabetes Mellitus in Adults.
    Ann Intern Med. 2022 May 3:OC1. doi: 10.7326/A21-0010.

  9. CHOU R, Dana T, Jungbauer R
    Update Alert 7: Masks for Prevention of Respiratory Virus Infections, Including SARS-CoV-2, in Health Care and Community Settings.
    Ann Intern Med. 2022 Mar 29. doi: 10.7326/L21-0783.

  10. Summary for Patients: PCR Testing Versus Rapid Antigen Testing at a Community Site During a COVID-19 Omicron Surge.
    Ann Intern Med. 2022 Mar 15. doi: 10.7326/P22-0002.

  11. SCHROM J, Marquez C, Pilarowski G, Wang CY, et al
    Comparison of SARS-CoV-2 Reverse Transcriptase Polymerase Chain Reaction and BinaxNOW Rapid Antigen Tests at a Community Site During an Omicron Surge : A Cross-Sectional Study.
    Ann Intern Med. 2022 Mar 15. doi: 10.7326/M22-0202.
    PubMed         Abstract available

  12. WISK LE, Nichol G, Elmore JG
    Toward Unbiased Evaluation of Postacute Sequelae of SARS-CoV-2 Infection: Challenges and Solutions for the Long Haul Ahead.
    Ann Intern Med. 2022 Mar 8. doi: 10.7326/M21-4664.

  13. MARZOLINI C, Kuritzkes DR, Marra F, Boyle A, et al
    Prescribing Nirmatrelvir-Ritonavir: How to Recognize and Manage Drug-Drug Interactions.
    Ann Intern Med. 2022 Mar 1. doi: 10.7326/M22-0281.

  14. KAKA AS, MacDonald R, Linskens EJ, Langsetmo L, et al
    Major Update 2: Remdesivir for Adults With COVID-19: A Living Systematic Review and Meta-analysis for the American College of Physicians Practice Points.
    Ann Intern Med. 2022 Mar 1. doi: 10.7326/M21-4784.
    PubMed         Abstract available

  15. QASEEM A, Yost J, Etxeandia-Ikobaltzeta I, Abraham GM, et al
    Should Remdesivir Be Used for the Treatment of Patients With COVID-19? Rapid, Living Practice Points From the American College of Physicians (Version 2, Update Alert 3).
    Ann Intern Med. 2022 Mar 1. doi: 10.7326/M21-4810.

  16. GAZIT S, Shlezinger R, Perez G, Lotan R, et al
    The Incidence of SARS-CoV-2 Reinfection in Persons With Naturally Acquired Immunity With and Without Subsequent Receipt of a Single Dose of BNT162b2 Vaccine : A Retrospective Cohort Study.
    Ann Intern Med. 2022 Feb 15. doi: 10.7326/M21-4130.
    PubMed         Abstract available

    Antiviral Res

  17. FOO CS, Abdelnabi R, Kaptein SJF, Zhang X, et al
    HIV protease inhibitors Nelfinavir and Lopinavir/Ritonavir markedly improve lung pathology in SARS-CoV-2-infected Syrian hamsters despite lack of an antiviral effect.
    Antiviral Res. 2022;202:105311.
    PubMed         Abstract available


  18. SIVAN M, Greenhalgh T, Milne R, Delaney B, et al
    Are vaccines a potential treatment for long covid?
    BMJ. 2022;377:o988.

  19. AYOUBKHANI D, Bermingham C, Pouwels KB, Glickman M, et al
    Trajectory of long covid symptoms after covid-19 vaccination: community based cohort study.
    BMJ. 2022;377:e069676.
    PubMed         Abstract available

  20. DYER O
    Covid-19: North Korean leader blames his party's incompetence after 393 000 cases of fever reported in a day.
    BMJ. 2022;377:o1228.

  21. CLARK KAA, Altin SE
    Calling time on the use of war metaphors in covid-19.
    BMJ. 2022;377:o1214.

  22. TAYLOR L
    Covid-19: WHO chief calls for a shift in China's "unsustainable" policy.
    BMJ. 2022;377:o1199.

  23. XIE N, Zhou Y
    Unresolving fever, headache, cough, and negative covid-19 PCR result.
    BMJ. 2022;377:e068645.

    Covid-19: Fourth dose of mRNA vaccines is safe and boosts immunity, study finds.
    BMJ. 2022;377:o1170.

  25. MONEER O, Daly G, Skydel JJ, Nyhan K, et al
    Agreement of treatment effects from observational studies and randomized controlled trials evaluating hydroxychloroquine, lopinavir-ritonavir, or dexamethasone for covid-19: meta-epidemiological study.
    BMJ. 2022;377:e069400.
    PubMed         Abstract available


  26. QU L, Yi Z, Shen Y, Lin L, et al
    Circular RNA vaccines against SARS-CoV-2 and emerging variants.
    Cell. 2022 Apr 1. pii: S0092-8674(22)00394-4. doi: 10.1016/j.cell.2022.
    PubMed         Abstract available

    Drug Saf

  27. MARTIN GL, Jouganous J, Savidan R, Bellec A, et al
    Validation of Artificial Intelligence to Support the Automatic Coding of Patient Adverse Drug Reaction Reports, Using Nationwide Pharmacovigilance Data.
    Drug Saf. 2022;45:535-548.
    PubMed         Abstract available

    Eur J Epidemiol

  28. LEVIN AT, Jylhava J, Religa D, Shallcross L, et al
    COVID-19 prevalence and mortality in longer-term care facilities.
    Eur J Epidemiol. 2022;37:227-234.
    PubMed         Abstract available

  29. AXFORS C, Ioannidis JPA
    Infection fatality rate of COVID-19 in community-dwelling elderly populations.
    Eur J Epidemiol. 2022;37:235-249.
    PubMed         Abstract available

    J Clin Microbiol

  30. YEUNG PS, Wang H, Sibai M, Solis D, et al
    Evaluation of a Rapid and Accessible Reverse Transcription-Quantitative PCR Approach for SARS-CoV-2 Variant of Concern Identification.
    J Clin Microbiol. 2022;60:e0017822.
    PubMed         Abstract available

  31. STANLEY S, Hamel DJ, Wolf ID, Riedel S, et al
    Limit of Detection for Rapid Antigen Testing of the SARS-CoV-2 Omicron and Delta Variants of Concern Using Live-Virus Culture.
    J Clin Microbiol. 2022;60:e0014022.

  32. BERRY GJ, Zhen W, Smith E, Manji R, et al
    Multicenter Evaluation of the BioFire Respiratory Panel 2.1 (RP2.1) for Detection of SARS-CoV-2 in Nasopharyngeal Swab Samples.
    J Clin Microbiol. 2022;60:e0006622.
    PubMed         Abstract available

    J Epidemiol Community Health

  33. KROMYDAS T, Green M, Craig P, Katikireddi SV, et al
    Comparing population-level mental health of UK workers before and during the COVID-19 pandemic: a longitudinal study using Understanding Society.
    J Epidemiol Community Health. 2022;76:527-536.
    PubMed         Abstract available

    Impact of COVID-19 pandemic on the workforce: from psychological distress to the Great Resignation.
    J Epidemiol Community Health. 2022;76:525-526.

  35. HENDERSON A, Fleming M, Cooper SA, Pell JP, et al
    COVID-19 infection and outcomes in a population-based cohort of 17 203 adults with intellectual disabilities compared with the general population.
    J Epidemiol Community Health. 2022;76:550-555.
    PubMed         Abstract available

  36. UTZET M, Bacigalupe A, Navarro A
    Occupational health, frontline workers and COVID-19 lockdown: new gender-related inequalities?
    J Epidemiol Community Health. 2022;76:537-543.
    PubMed         Abstract available

  37. SAVILLE CWN, Thomas DR
    Social capital and geographical variation in the incidence of COVID-19: an ecological study.
    J Epidemiol Community Health. 2022;76:544-549.
    PubMed         Abstract available

    How infodemic intoxicates public health surveillance: from a big to a slow data culture.
    J Epidemiol Community Health. 2022;76:623-625.

    J Immunol

  39. LOUIE AY, Tingling J, Dray E, Hussain J, et al
    Dietary Cholesterol Causes Inflammatory Imbalance and Exacerbates Morbidity in Mice Infected with Influenza A Virus.
    J Immunol. 2022;208:2523-2539.
    PubMed         Abstract available

  40. TAN HX, Wragg KM, Kelly HG, Esterbauer R, et al
    Cutting Edge: SARS-CoV-2 Infection Induces Robust Germinal Center Activity in the Human Tonsil.
    J Immunol. 2022;208:2267-2271.
    PubMed         Abstract available

    J Infect

  41. CHENG D, Dong Y, Wen S, Shi C, et al
    A child with acute respiratory distress syndrome caused by avian influenza H3N8 virus.
    J Infect. 2022 May 13. pii: S0163-4453(22)00288.

    J Infect Dis

  42. RIEKE GJ, van Bremen K, Bischoff J, To Vinh M, et al
    Induction of NK cell-mediated antibody-dependent cellular cytotoxicity (ADCC) against SARS-CoV-2 after natural infection is more potent than after vaccination.
    J Infect Dis. 2022 Mar 22. pii: 6552258. doi: 10.1093.
    PubMed         Abstract available

    Antibodies: A Double Leg Takedown Against COVID-19.
    J Infect Dis. 2022;225:1685-1687.

  44. PATI A, Nayak N, Sarangi S, Barik D, et al
    CCL5 rs2107538 Variant Is Associated With Protection Against SARS-CoV-2 Infection and Related Mortality: A Population-Based Study.
    J Infect Dis. 2022;225:1865-1866.

  45. PEREZ-GARCIA F, Martin-Vicente M, Bermejo-Martin JF, Resino S, et al
    Reply to Pati et al.
    J Infect Dis. 2022;225:1866-1868.

  46. LIU J, Huang B, Li G, Chang X, et al
    Immunogenicity and Safety of a Three-Dose Regimen of a SARS-CoV-2 Inactivated Vaccine in Adults: A Randomized, Double-blind, Placebo-controlled Phase 2 Trial.
    J Infect Dis. 2021 Dec 27. pii: 6484920. doi: 10.1093.
    PubMed         Abstract available

  47. LEWIS NM, Naioti EA, Self WH, Ginde AA, et al
    Effectiveness of mRNA vaccines in preventing COVID-19 hospitalization by age and burden of chronic medical conditions among immunocompetent US adults, March-August 2021.
    J Infect Dis. 2021 Dec 21. pii: 6472998. doi: 10.1093.
    PubMed         Abstract available

  48. LEWNARD JA, Bruxvoort KJ, Fischer H, Hong VX, et al
    Prevention of COVID-19 among older adults receiving pneumococcal conjugate vaccine suggests interactions between Streptococcus pneumoniae and SARS-CoV-2 in the respiratory tract.
    J Infect Dis. 2021 Mar 9. pii: 6164926. doi: 10.1093.
    PubMed         Abstract available

    J Virol

  49. VANDOORN E, Stadejek W, Parys A, Chepkwony S, et al
    Pathobiology of an NS1-Truncated H3N2 Swine Influenza Virus Strain in Pigs.
    J Virol. 2022 May 12:e0051922. doi: 10.1128/jvi.00519.
    PubMed         Abstract available

  50. ZHENG XS, Wang Q, Min J, Shen XR, et al
    Single-Cell Landscape of Lungs Reveals Key Role of Neutrophil-Mediated Immunopathology during Lethal SARS-CoV-2 Infection.
    J Virol. 2022 Apr 14:e0003822. doi: 10.1128/jvi.00038.
    PubMed         Abstract available

  51. DESCHAMBAULT Y, Lynch J, Warner B, Tierney K, et al
    Single Immunization with Recombinant ACAM2000 Vaccinia Viruses Expressing the Spike and the Nucleocapsid Proteins Protects Hamsters against SARS-CoV-2-Caused Clinical Disease.
    J Virol. 2022 Apr 12:e0038922. doi: 10.1128/jvi.00389.
    PubMed         Abstract available


  52. RUBIN R
    First Breathalyzer Test to Diagnose COVID-19.
    JAMA. 2022;327:1860.

    Rapid Antigen Tests for SARS-CoV-2.
    JAMA. 2022;327:1925-1926.

  54. GANS JS, Goldfarb A, Rosella L
    Rapid Antigen Tests for SARS-CoV-2-Reply.
    JAMA. 2022;327:1926.

  55. HOURY DE, Simon TR, Crosby AE
    Firearm Homicide and Suicide During the COVID-19 Pandemic: Implications for Clinicians and Health Care Systems.
    JAMA. 2022 May 10. pii: 2792080. doi: 10.1001/jama.2022.6924.

    Four Vaccine Doses Prevented Severe Omicron COVID-19 Better Than 3.
    JAMA. 2022;327:1748.

    Two mRNA COVID-19 Vaccines Stimulate Different Immune Responses.
    JAMA. 2022;327:1748.

  58. MANGURIAN C, Fitelson EM, Epel E
    COVID-19 and Lessons to Improve Preparedness for the Next Pandemic.
    JAMA. 2022;327:1822-1823.

  59. CHEN J, Al-Azzawi ZAM, Taifour T
    Testing, Surveillance, and Mitigation Strategies for COVID-19.
    JAMA. 2022;327:1824-1825.

    Strategy for the "New Normal" of Life With COVID.
    JAMA. 2022;327:1823-1824.

  61. NUZZO JB, Gostin LO
    COVID-19 and Lessons to Improve Preparedness for the Next Pandemic-Reply.
    JAMA. 2022;327:1823.

  62. EMANUEL EJ, Michaels D, Bright RA
    Testing, Surveillance, and Mitigation Strategies for COVID-19-Reply.
    JAMA. 2022;327:1825.

  63. EMANUEL EJ, Osterholm M, Gounder CR
    Strategy for the "New Normal" of Life With COVID-Reply.
    JAMA. 2022;327:1824.

  64. KUEHN BM
    mRNA Booster Improves a COVID-19 Vaccine's Effectiveness.
    JAMA. 2022;327:1749.

  65. MARKS P, Woodcock J, Califf R
    COVID-19 Vaccination-Becoming Part of the New Normal.
    JAMA. 2022 May 2. pii: 2792030. doi: 10.1001/jama.2022.7469.

    The Pandemic Determinants of Health.
    JAMA. 2022;327:1869.

  67. RUBIN R
    The COVID-19 Pandemic Rages on for People Who Are Immunocompromised.
    JAMA. 2022 Apr 27. pii: 2791868. doi: 10.1001/jama.2022.7281.

  68. SURAN M
    Stagnant US Mammography Rates and the Influence of COVID-19.
    JAMA. 2022 Apr 20. pii: 2791573. doi: 10.1001/jama.2022.4295.

  69. NATTINO G, Castiglioni S, Cereda D, Della Valle PG, et al
    Association Between SARS-CoV-2 Viral Load in Wastewater and Reported Cases, Hospitalizations, and Vaccinations in Milan, March 2020 to November 2021.
    JAMA. 2022 Apr 1. pii: 2790911. doi: 10.1001/jama.2022.4908.


  70. YUAN S
    Zero COVID in China: what next?
    Lancet. 2022;399:1856-1857.

  71. KOLA L, Kumar M, Kohrt BA, Fatodun T, et al
    Strengthening public mental health during and after the acute phase of the COVID-19 pandemic.
    Lancet. 2022 Mar 24. pii: S0140-6736(22)00523.

    MMWR Morb Mortal Wkly Rep

  72. KEGLER SR, Simon TR, Zwald ML, Chen MS, et al
    Vital Signs: Changes in Firearm Homicide and Suicide Rates - United States, 2019-2020.
    MMWR Morb Mortal Wkly Rep. 2022;71:656-663.
    PubMed         Abstract available

    N Engl J Med

  73. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: What to Make of Covid-19 Hot Spots.
    N Engl J Med. 2022;386:e63.

  74. RUBIN EJ, Baden LR, Lipsitch M, Morrissey S, et al
    Audio Interview: Forecasting the Future of Covid.
    N Engl J Med. 2022;386:e58.

    Intrinsic Severity of the SARS-CoV-2 Omicron Variant. Reply.
    N Engl J Med. 2022 Apr 20. pii: 10.1056/NEJMc2203679.

    Intrinsic Severity of the SARS-CoV-2 Omicron Variant.
    N Engl J Med. 2022 Apr 20. pii: 10.1056/NEJMc2203679.

  77. YOON SK, Hegmann KT, Thiese MS, Burgess JL, et al
    Protection with a Third Dose of mRNA Vaccine against SARS-CoV-2 Variants in Frontline Workers.
    N Engl J Med. 2022 Apr 6. doi: 10.1056/NEJMc2201821.

  78. LEE KC, Morgan AU, Chaiyachati KH, Asch DA, et al
    Pulse Oximetry for Monitoring Patients with Covid-19 at Home - A Pragmatic, Randomized Trial.
    N Engl J Med. 2022 Apr 6. doi: 10.1056/NEJMc2201541.

  79. PRICE AM, Olson SM, Newhams MM, Halasa NB, et al
    BNT162b2 Protection against the Omicron Variant in Children and Adolescents.
    N Engl J Med. 2022 Mar 30. doi: 10.1056/NEJMoa2202826.
    PubMed         Abstract available

  80. MOREIRA ED JR, Kitchin N, Xu X, Dychter SS, et al
    Safety and Efficacy of a Third Dose of BNT162b2 Covid-19 Vaccine.
    N Engl J Med. 2022 Mar 23. doi: 10.1056/NEJMoa2200674.
    PubMed         Abstract available

  81. ABU-RADDAD LJ, Chemaitelly H, Ayoub HH, AlMukdad S, et al
    Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar.
    N Engl J Med. 2022 Mar 9. doi: 10.1056/NEJMoa2200797.
    PubMed         Abstract available

    PLoS Comput Biol

  82. DE MAIO N, Boulton W, Weilguny L, Walker CR, et al
    phastSim: Efficient simulation of sequence evolution for pandemic-scale datasets.
    PLoS Comput Biol. 2022;18:e1010056.
    PubMed         Abstract available

  83. KLINK GV, Kalinina OV, Bazykin GA
    Phylogenetic inference of changes in amino acid propensities with single-position resolution.
    PLoS Comput Biol. 2022;18:e1009878.
    PubMed         Abstract available

    PLoS Genet

  84. WANG C, Chen L, Chen Y, Jia W, et al
    Abnormal global alternative RNA splicing in COVID-19 patients.
    PLoS Genet. 2022;18:e1010137.
    PubMed         Abstract available

    PLoS Med

  85. VAN GILS MJ, Lavell A, van der Straten K, Appelman B, et al
    Antibody responses against SARS-CoV-2 variants induced by four different SARS-CoV-2 vaccines in health care workers in the Netherlands: A prospective cohort study.
    PLoS Med. 2022;19:e1003991.
    PubMed         Abstract available

  86. ALTARE C, Kostandova N, OKeeffe J, Hayek H, et al
    COVID-19 epidemiology and changes in health service utilization in Azraq and Zaatari refugee camps in Jordan: A retrospective cohort study.
    PLoS Med. 2022;19:e1003993.
    PubMed         Abstract available

    PLoS One

  87. RICARDO AC, Chen J, Toth-Manikowski SM, Meza N, et al
    Hispanic ethnicity and mortality among critically ill patients with COVID-19.
    PLoS One. 2022;17:e0268022.
    PubMed         Abstract available

  88. YLITALO KR, Cox W, Lucas R, Smith J, et al
    Telephone-based support for physical activity: Results and lessons learned during the COVID-19 pandemic.
    PLoS One. 2022;17:e0268429.
    PubMed         Abstract available

  89. GUGLIELMI V, Colangeli L, Scipione V, Ballacci S, et al
    Inflammation, underweight, malignancy and a marked catabolic state as predictors for worse outcomes in COVID-19 patients with moderate-to-severe disease admitted to Internal Medicine Unit.
    PLoS One. 2022;17:e0268432.
    PubMed         Abstract available

  90. ACKAH M, Ameyaw L, Gazali Salifu M, Afi Asubonteng DP, et al
    COVID-19 vaccine acceptance among health care workers in Africa: A systematic review and meta-analysis.
    PLoS One. 2022;17:e0268711.
    PubMed         Abstract available

  91. RICH C, Mavhu W, France NF, Munatsi V, et al
    Exploring the beliefs, experiences and impacts of HIV-related self-stigma amongst adolescents and young adults living with HIV in Harare, Zimbabwe: A qualitative study.
    PLoS One. 2022;17:e0268498.
    PubMed         Abstract available

  92. CHYBA M, Kunwar P, Mileyko Y, Tong A, et al
    COVID-19 heterogeneity in islands chain environment.
    PLoS One. 2022;17:e0263866.
    PubMed         Abstract available

  93. GAIKWAD UN, Bose O, Padhi A, Jindal A, et al
    A retrospective observational insight into COVID-19 exposures resulting from personal protective equipment (PPE) breaches.
    PLoS One. 2022;17:e0268582.
    PubMed         Abstract available

  94. SHEIKHI F, Yousefian N, Tehranipoor P, Kowsari Z, et al
    Estimation of the basic reproduction number of Alpha and Delta variants of COVID-19 pandemic in Iran.
    PLoS One. 2022;17:e0265489.
    PubMed         Abstract available

  95. SOUZA APG, Mota CMM, Rosa AGF, Figueiredo CJJ, et al
    A spatial-temporal analysis at the early stages of the COVID-19 pandemic and its determinants: The case of Recife neighborhoods, Brazil.
    PLoS One. 2022;17:e0268538.
    PubMed         Abstract available

  96. UNRUH LH, Dharmapuri S, Xia Y, Soyemi K, et al
    Health disparities and COVID-19: A retrospective study examining individual and community factors causing disproportionate COVID-19 outcomes in Cook County, Illinois.
    PLoS One. 2022;17:e0268317.
    PubMed         Abstract available

  97. IWAMOTO M, Ukimura A, Ogawa T, Kawanishi F, et al
    Association between history of HBV vaccine response and anti-SARS-CoV-2 spike antibody response to the BioNTech/Pfizer's BNT162b2 mRNA SARS-CoV-2 vaccine among healthcare workers in Japan: A prospective observational study.
    PLoS One. 2022;17:e0268529.
    PubMed         Abstract available

  98. SONIS J, Pathman DE, Read S, Gaynes BN, et al
    A national study of moral distress among U.S. internal medicine physicians during the COVID-19 pandemic.
    PLoS One. 2022;17:e0268375.
    PubMed         Abstract available

  99. BERIHUN G, Adane M, Walle Z, Abebe M, et al
    Access to and challenges in water, sanitation, and hygiene in healthcare facilities during the early phase of the COVID-19 pandemic in Ethiopia: A mixed-methods evaluation.
    PLoS One. 2022;17:e0268272.
    PubMed         Abstract available

  100. STOYKOVA Z, Kostadinova T, Todorova T, Niyazi D, et al
    Dealing with inconclusive SARS-CoV-2 PCR samples-Our experience.
    PLoS One. 2022;17:e0268187.
    PubMed         Abstract available

  101. KIKUCHI K, Islam R, Nishikitani M, Sato Y, et al
    Women's health status before and during the COVID-19 pandemic in rural Bangladesh: A prospective longitudinal study.
    PLoS One. 2022;17:e0266141.
    PubMed         Abstract available

  102. DENK J, Burmester A, Kandziora M, Clement M, et al
    The impact of COVID-19 on music consumption and music spending.
    PLoS One. 2022;17:e0267640.
    PubMed         Abstract available

  103. DUFEIL E, Kenfack B, Tincho E, Fouogue J, et al
    Addition of digital VIA/VILI to conventional naked-eye examination for triage of HPV-positive women: A study conducted in a low-resource setting.
    PLoS One. 2022;17:e0268015.
    PubMed         Abstract available

  104. MCGEOCH LJ, Thornton HV, Blair PS, Christensen H, et al
    Prognostic value of upper respiratory tract microbes in children presenting to primary care with respiratory infections: A prospective cohort study.
    PLoS One. 2022;17:e0268131.
    PubMed         Abstract available

  105. RAZAVI S, Farrokhnia N, Davoody N
    Nurses' experience of using video consultation in a digital care setting and its impact on their workflow and communication.
    PLoS One. 2022;17:e0264876.
    PubMed         Abstract available

  106. TANG D, Macniven R, Bender N, Jones C, et al
    Development, implementation and evaluation of the online Movement, Interaction and Nutrition for Greater Lifestyles in the Elderly (MINGLE) program: The protocol for a pilot trial.
    PLoS One. 2022;17:e0267581.
    PubMed         Abstract available

    It's Time to be disgusting about COVID-19: Effect of disgust priming on COVID-19 public health compliance among liberals and conservatives.
    PLoS One. 2022;17:e0267735.
    PubMed         Abstract available

  108. KIM JH, Baek AR, Lee SI, Kim WY, et al
    ROX index and SpO2/FiO2 ratio for predicting high-flow nasal cannula failure in hypoxemic COVID-19 patients: A multicenter retrospective study.
    PLoS One. 2022;17:e0268431.
    PubMed         Abstract available

  109. MARQUEZ LK, Ingiliz P, Boesecke C, Krznaric I, et al
    Establishing a framework towards monitoring HCV microelimination among men who have sex with men living with HIV in Germany: A modeling analysis.
    PLoS One. 2022;17:e0267853.
    PubMed         Abstract available

  110. PAGEN DME, Brinkhues S, Dukers-Muijrers NHTM, den Heijer CDJ, et al
    Exposure factors associated with SARS-CoV-2 seroprevalence during the first eight months of the COVID-19 pandemic in the Netherlands: A cross-sectional study.
    PLoS One. 2022;17:e0268057.
    PubMed         Abstract available

  111. VARAS S, Elorrieta F, Vargas C, Villalobos Dintrans P, et al
    Factors associated with change in adherence to COVID-19 personal protection measures in the Metropolitan Region, Chile.
    PLoS One. 2022;17:e0267413.
    PubMed         Abstract available

  112. BENACH J, Cash-Gibson L, Rojas-Gualdron DF, Padilla-Pozo A, et al
    Inequalities in COVID-19 inequalities research: Who had the capacity to respond?
    PLoS One. 2022;17:e0266132.
    PubMed         Abstract available

  113. SETIADI W, Rozi IE, Safari D, Daningrat WOD, et al
    Prevalence and epidemiological characteristics of COVID-19 after one year of pandemic in Jakarta and neighbouring areas, Indonesia: A single center study.
    PLoS One. 2022;17:e0268241.
    PubMed         Abstract available

  114. BUTLER JZ, Carson M, Rios-Fetchko F, Vargas R, et al
    COVID-19 vaccination readiness among multiple racial and ethnic groups in the San Francisco Bay Area: A qualitative analysis.
    PLoS One. 2022;17:e0266397.
    PubMed         Abstract available

  115. OBA J, Taniguchi H, Sato M, Takanashi M, et al
    SARS-CoV-2 RT-qPCR testing of pooled saliva samples: A case study of 824 asymptomatic individuals and a questionnaire survey in Japan.
    PLoS One. 2022;17:e0263700.
    PubMed         Abstract available

  116. OLU-ABIODUN O, Abiodun O, Okafor N
    COVID-19 vaccination in Nigeria: A rapid review of vaccine acceptance rate and the associated factors.
    PLoS One. 2022;17:e0267691.
    PubMed         Abstract available

  117. LU S, Duplat D, Benitez-Bolivar P, Leon C, et al
    Multicenter international assessment of a SARS-CoV-2 RT-LAMP test for point of care clinical application.
    PLoS One. 2022;17:e0268340.
    PubMed         Abstract available

  118. MENDOZA-RUVALCABA NM, Gutierrez-Herrera R, Lopez C, Hesse H, et al
    Impact of quarantine due to COVID-19 pandemic on health and lifestyle conditions in older adults from Centro American countries.
    PLoS One. 2022;17:e0264087.
    PubMed         Abstract available

  119. STEPHENSON A, Howes S, Murphy PJ, Deutsch JE, et al
    Factors influencing the delivery of telerehabilitation for stroke: A systematic review.
    PLoS One. 2022;17:e0265828.
    PubMed         Abstract available

  120. FUCHS L, Galante O, Almog Y, Dayan RR, et al
    Point of Care Lung Ultrasound Injury Score-A simple and reliable assessment tool in COVID-19 patients (PLIS I): A retrospective study.
    PLoS One. 2022;17:e0267506.
    PubMed         Abstract available

  121. FERNANDEZ-GUZMAN D, Soriano-Moreno DR, Ccami-Bernal F, Velasquez-Fernandez R, et al
    Factors associated with prevention practices against COVID-19 in the Peruvian population: Disparities between rural and urban areas.
    PLoS One. 2022;17:e0267625.
    PubMed         Abstract available

  122. SHUVO SD, Hossain MS, Riazuddin M, Mazumdar S, et al
    Factors influencing low-income households' food insecurity in Bangladesh during the COVID-19 lockdown.
    PLoS One. 2022;17:e0267488.
    PubMed         Abstract available

  123. FREUND O, Tau L, Weiss TE, Zornitzki L, et al
    Associations of vaccine status with characteristics and outcomes of hospitalized severe COVID-19 patients in the booster era.
    PLoS One. 2022;17:e0268050.
    PubMed         Abstract available

  124. GONG Y, Zhao G
    Wealth, health, and beyond: Is COVID-19 less likely to spread in rich neighborhoods?
    PLoS One. 2022;17:e0267487.
    PubMed         Abstract available

  125. PALO SK, Dubey S, Negi S, Sahay MR, et al
    Effective interventions to ensure MCH (Maternal and Child Health) services during pandemic related health emergencies (Zika, Ebola, and COVID-19): A systematic review.
    PLoS One. 2022;17:e0268106.
    PubMed         Abstract available

  126. YU Y, Lau MMC, Lau JTF
    Application of the protection motivation theory to understand determinants of compliance with the measure of banning gathering size >4 in all public areas for controlling COVID-19 in a Hong Kong Chinese adult general population.
    PLoS One. 2022;17:e0268336.
    PubMed         Abstract available

  127. BWOGI J, Lutalo T, Tushabe P, Bukenya H, et al
    Field evaluation of the performance of seven Antigen Rapid diagnostic tests for the diagnosis of SARs-CoV-2 virus infection in Uganda.
    PLoS One. 2022;17:e0265334.
    PubMed         Abstract available

  128. KING KL, Wilson S, Napolitano JM, Sell KJ, et al
    SARS-CoV-2 variants of concern Alpha and Delta show increased viral load in saliva.
    PLoS One. 2022;17:e0267750.
    PubMed         Abstract available

    Proc Natl Acad Sci U S A

  129. ZHU X, Han J, Sun W, Puente-Massaguer E, et al
    Influenza chimeric hemagglutinin structures in complex with broadly protective antibodies to the stem and trimer interface.
    Proc Natl Acad Sci U S A. 2022;119:e2200821119.
    PubMed         Abstract available

  130. BAXTER-KING R, Brown JR, Enos RD, Naeim A, et al
    How local partisan context conditions prosocial behaviors: Mask wearing during COVID-19.
    Proc Natl Acad Sci U S A. 2022;119:e2116311119.
    PubMed         Abstract available

  131. ZHANG C, Verma A, Feng Y, Melo MCR, et al
    Impact of natural selection on global patterns of genetic variation and association with clinical phenotypes at genes involved in SARS-CoV-2 infection.
    Proc Natl Acad Sci U S A. 2022;119:e2123000119.
    PubMed         Abstract available

  132. MANRY J, Bastard P, Gervais A, Le Voyer T, et al
    The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies.
    Proc Natl Acad Sci U S A. 2022;119:e2200413119.
    PubMed         Abstract available

  133. KINGSTAD-BAKKE B, Lee W, Chandrasekar SS, Gasper DJ, et al
    Vaccine-induced systemic and mucosal T cell immunity to SARS-CoV-2 viral variants.
    Proc Natl Acad Sci U S A. 2022;119:e2118312119.
    PubMed         Abstract available

  134. TORRES JL, Ozorowski G, Andreano E, Liu H, et al
    Structural insights of a highly potent pan-neutralizing SARS-CoV-2 human monoclonal antibody.
    Proc Natl Acad Sci U S A. 2022;119:e2120976119.
    PubMed         Abstract available


  135. TSAI SY, Yeh TY, Chiu NC, Huang CT, et al
    National safety surveillance of quadrivalent recombinant influenza vaccine in Taiwan during NH 20/21.
    Vaccine. 2022 May 13. pii: S0264-410X(22)00588.
    PubMed         Abstract available

  136. GUPTA C, Sachdeva A, Khamar J, Bu C, et al
    Effectiveness of the influenza vaccine at reducing adverse events in patients with heart failure: A systematic review and meta-analysis.
    Vaccine. 2022 May 10. pii: S0264-410X(22)00468.
    PubMed         Abstract available

  137. NASREEN S, Calzavara A, Buchan SA, Thampi N, et al
    Background incidence rates of adverse events of special interest related to COVID-19 vaccines in Ontario, Canada, 2015 to 2020, to inform COVID-19 vaccine safety surveillance.
    Vaccine. 2022 Apr 27. pii: S0264-410X(22)00520.
    PubMed         Abstract available

  138. PERSSON U, Olofsson S, Althin R, Palmborg A, et al
    Acceptance and application of a broad population health perspective when evaluating vaccine.
    Vaccine. 2022 May 4. pii: S0264-410X(22)00425.
    PubMed         Abstract available

  139. NANTANEE R, Aikphaibul P, Jaru-Ampornpan P, Sodsai P, et al
    Immunogenicity and reactogenicity after booster dose with AZD1222 via intradermal route among adult who had received CoronaVac.
    Vaccine. 2022 May 2. pii: S0264-410X(22)00521.
    PubMed         Abstract available

  140. DEMIR E, Dheir H, Safak S, Serra Artan A, et al
    Differences in clinical outcomes of COVID-19 among vaccinated and unvaccinated kidney transplant recipients.
    Vaccine. 2022 Apr 27. pii: S0264-410X(22)00519.
    PubMed         Abstract available

  141. MASUDA T, Murakami K, Sugiura K, Sakui S, et al
    Safety and immunogenicity of NVX-CoV2373 (TAK-019) vaccine in healthy Japanese adults: Interim report of a phase I/II randomized controlled trial.
    Vaccine. 2022 Apr 29. pii: S0264-410X(22)00463.
    PubMed         Abstract available

  142. MORO PL, Olson CK, Clark E, Marquez P, et al
    Post-authorization surveillance of adverse events following COVID-19 vaccines in pregnant persons in the vaccine adverse event reporting system (VAERS), December 2020 - October 2021.
    Vaccine. 2022 Apr 12. pii: S0264-410X(22)00447.
    PubMed         Abstract available

  143. SALO H, Lehtonen T, Auranen K, Baum U, et al
    Predictors of hospitalisation and death due to SARS-CoV-2 infection in Finland: A population-based register study with implications to vaccinations.
    Vaccine. 2022 Apr 22. pii: S0264-410X(22)00495.
    PubMed         Abstract available

  144. MARKOVITZ NH, Strome AL, Patel PK
    Commentary: "The vaccine Selfie" and its influence on COVID-19 vaccine acceptance.
    Vaccine. 2022 Apr 26. pii: S0264-410X(22)00503.

  145. SINGH BK, Walker J, Paul P, Reddy S, et al
    De-escalation of asymptomatic testing and potential of future COVID-19 outbreaks in US nursing homes amidst rising community vaccination coverage: A modeling study.
    Vaccine. 2022 Apr 18. pii: S0264-410X(22)00467.
    PubMed         Abstract available

  146. TAMANG ST, Dorji T
    COVID-19 vaccinations in Bhutan - Mix-and-Match to Boosters: An experience.
    Vaccine. 2022 Apr 22. pii: S0264-410X(22)00499.
    PubMed         Abstract available

  147. MCCOSKER LK, El-Heneidy A, Seale H, Ware RS, et al
    Strategies to improve vaccination rates in people who are homeless: A systematic review.
    Vaccine. 2022 Apr 25. pii: S0264-410X(22)00436.
    PubMed         Abstract available

  148. ANTONOPOULOU T, Athanassakis I
    SARS-CoV-2 immunogenicity: Is S protein the best target for vaccination?
    Vaccine. 2022 Apr 22. pii: S0264-410X(22)00501.

  149. SHEA LL, Becker A, Lee BK, Miller KK, et al
    Self-reported COVID-19 vaccination acceptance and hesitancy among autistic adults.
    Vaccine. 2022 Apr 22. pii: S0264-410X(22)00500.
    PubMed         Abstract available

  150. STRECKENBACH B, Baldt J, Heidler F, Frahm N, et al
    General vaccination willingness and current vaccination status in relation to clinical and psychological variables in patients with multiple sclerosis.
    Vaccine. 2022 Apr 23. pii: S0264-410X(22)00428.
    PubMed         Abstract available

  151. LI L, Honda-Okubo Y, Baldwin J, Bowen R, et al
    Covax-19/Spikogen(R) vaccine based on recombinant spike protein extracellular domain with Advax-CpG55.2 adjuvant provides single dose protection against SARS-CoV-2 infection in hamsters.
    Vaccine. 2022 Apr 18. pii: S0264-410X(22)00469.
    PubMed         Abstract available

  152. WANLAPAKORN N, Suntronwong N, Phowatthanasathian H, Yorsaeng R, et al
    Immunogenicity of heterologous inactivated and adenoviral-vectored COVID-19 vaccine: Real-world data.
    Vaccine. 2022 Apr 18. pii: S0264-410X(22)00471.
    PubMed         Abstract available

  153. SAADE A, Cha L, Tadie E, Jurado B, et al
    Delay between COVID-19 complete vaccination and SARS-CoV-2 infection among healthcare workers.
    Vaccine. 2022 Apr 18. pii: S0264-410X(22)00473.
    PubMed         Abstract available

  154. CHRISSIAN AA, Oyoyo UE, Patel P, Lawrence Beeson W, et al
    Impact of COVID-19 vaccine-associated side effects on health care worker absenteeism and future booster vaccination.
    Vaccine. 2022 Apr 18. pii: S0264-410X(22)00474.
    PubMed         Abstract available

  155. YAN Y, Naito T, Tabe Y, Ito K, et al
    Increased delta variant SARS-CoV-2 infections in a highly vaccinated medical center in Japan.
    Vaccine. 2022 Apr 12. pii: S0264-410X(22)00445.
    PubMed         Abstract available

  156. XU S, Hong V, Sy LS, Glenn SC, et al
    Changes in incidence rates of outcomes of interest in vaccine safety studies during the COVID-19 pandemic.
    Vaccine. 2022 Apr 18. pii: S0264-410X(22)00464.
    PubMed         Abstract available

  157. PRAMOD S, Govindan D, Ramasubramani P, Kar SS, et al
    Effectiveness of Covishield vaccine in preventing Covid-19 - A test-negative case-control study.
    Vaccine. 2022 Feb 9. pii: S0264-410X(22)00138.
    PubMed         Abstract available


  158. ZHU Y, Scholle F, Kisthardt SC, Xie DY, et al
    Flavonols and dihydroflavonols inhibit the main protease activity of SARS-CoV-2 and the replication of human coronavirus 229E.
    Virology. 2022;571:21-33.
    PubMed         Abstract available

    Virus Res

  159. YANG F, Zhu L, Liu F, Cheng L, et al
    Generation and characterization of monoclonal antibodies against the hemagglutinin of H3N2 influenza A viruses.
    Virus Res. 2022 May 17:198815. doi: 10.1016/j.virusres.2022.198815.
    PubMed         Abstract available

  160. ALMEIDA F, Santos LA, Trigueiro-Louro JM, RebelodeAndrade H, et al
    Optimization of A(H1N1)pdm09 vaccine seed viruses: the source of PB1 and HA vRNA as a major determinant for antigen yield.
    Virus Res. 2022 Apr 30:198795. doi: 10.1016/j.virusres.2022.198795.
    PubMed         Abstract available

  161. ALCANTARA LCJ, Nogueira E, Shuab G, Tosta S, et al
    SARS-CoV-2 epidemic in Brazil: how the displacement of variants has driven distinct epidemic waves.
    Virus Res. 2022;315:198785.
    PubMed         Abstract available

  162. DE AMARAL M, Ienes-Lima J
    Anurans against SARS-CoV-2: A review of the potential antiviral action of anurans cutaneous peptides.
    Virus Res. 2022;315:198769.
    PubMed         Abstract available

  163. GAIARSA S, Giardina F, Batisti Biffignandi G, Ferrari G, et al
    Comparative analysis of SARS-CoV-2 quasispecies in the upper and lower respiratory tract shows an ongoing evolution in the spike cleavage site.
    Virus Res. 2022;315:198786.
    PubMed         Abstract available

  164. SARKAR A, Paul S, Singh C, Chowdhury N, et al
    A novel plant lectin, NTL-125, interferes with SARS-CoV-2 interaction with hACE2.
    Virus Res. 2022;315:198768.
    PubMed         Abstract available

  165. BANSAL K, Kumar S
    Mutational cascade of SARS-CoV-2 leading to evolution and emergence of omicron variant.
    Virus Res. 2022;315:198765.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Influenza is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.